XML 32 R22.htm IDEA: XBRL DOCUMENT v3.23.2
Revenue (Tables)
9 Months Ended
Jun. 30, 2023
Revenue From Contract With Customer [Abstract]  
Summary of Revenues Disaggregated by Product Classification and Reportable Segment

The following table presents the Company’s revenues disaggregated by product classification and by reportable segment.

 

Three Months Ended June 30,

 

 

Nine Months Ended June 30,

 

(In thousands)

2023

 

 

2022

 

 

2023

 

 

2022

 

Medical Device

 

 

 

 

 

Product sales

$

9,299

 

 

$

6,741

 

 

$

25,593

 

 

$

19,970

 

Royalties

 

8,220

 

 

 

7,771

 

 

 

23,702

 

 

 

23,015

 

License fees

 

25,933

 

 

 

1,024

 

 

 

28,645

 

 

 

3,723

 

Research, development and other

 

2,562

 

 

 

1,992

 

 

 

6,799

 

 

 

6,181

 

Medical Device Revenue

 

46,014

 

 

 

17,528

 

 

 

84,739

 

 

 

52,889

 

In Vitro Diagnostics

 

 

 

 

 

 

 

 

 

 

 

Product sales

 

6,368

 

 

 

7,178

 

 

 

19,658

 

 

 

20,257

 

Research, development and other

 

101

 

 

 

148

 

 

 

217

 

 

 

817

 

In Vitro Diagnostics Revenue

 

6,469

 

 

 

7,326

 

 

 

19,875

 

 

 

21,074

 

Total Revenue

$

52,483

 

 

$

24,854

 

 

$

104,614

 

 

$

73,963